A Randomized Controlled Trial Study Protocol of Modified Mahuang-Fuzi-Xixin Decoction in the Treatment of Patients with Mild Bronchial Asthma During Acute Exacerbation

Affiliated Hospital of Chengdu University of traditional Chinese Medicine0 sitesStarted: TBDLast updated: February 20, 2023

Conditions

Trial Snapshot

No summary available.

•1. Patients aged between 18 and 45 years old, both male and female;
•2. According to the guidelines for prevention and treatment of bronchial asthma formulated by the asthma group of Respiratory Society of Chinese Medical Association in 2016, bronchial asthma was diagnosed as mild in acute attack stage;
•3. Patients who meet the diagnostic criteria of TCM asthma syndrome lung kidney yang deficiency syndrome;
•4. Patients with good ability to read, understand and write research related materials, and voluntarily comply with all trial requirements;
•5. Patients who voluntarily participated in the study and signed informed consent.

•1. Patients with respiratory tract infection within 4 weeks;
•2. Patients with chronic obstructive pulmonary disease, interstitial lung disease, active pulmonary tuberculosis, bronchiectasis and other chronic lung diseases that need intervention or treatment;
•3. Patients with severe mental and psychological disorders, cardiovascular, liver and kidney, endocrine, hematopoietic system, malignant tumor and other serious primary diseases;
•4. Patients who take antibiotics within 3 months and take yogurt or probiotics within 1 month;
•5. Patients who are unwilling or unable to change the current treatment plan;
•6. Patients who are known to be allergic to the test drug or some traditional Chinese medicine in the test drug;
•7. Women in lactation, pregnancy or preparing for pregnancy;
•8. Patients who have participated in other clinical studies in recent six months.

Sponsor

Affiliated Hospital of Chengdu University of traditional Chinese Medicine